Arisaph Pharmaceuticals, Inc.

Boston, MA 02110

SBIR Award Summary

Total Number of Awards 8
Total Value of Awards $2.62MM
First Award Date 09/23/11
Most Recent Award Date 09/22/15

Key Personnel

Last Name Name Awards Contact
Bachovchin William W Bachovchin 7
Jones Barry Jones 7
BENEDICT CLAUDE BENEDICT 1

8 Awards Won

Phase 1 SBIR

Agency: Department of Health & Human Services
Topic: PA-14-071
Budget: 09/22/15 - 06/30/16

DESCRIPTION (provided by applicant): Nonalcoholic steatohepatitis (NASH) characterized by liver steatosis with hepatocellular injury and inflammation is a potentially serious condition with up to 25% of patients progressing to cirrhosis with complications of portal hypertension, liver failure, and hepatocellular carcinoma. NASH is highly prevale...

Phase 2 STTR

Agency: Department of Health & Human Services
Topic: PA-13-235
Budget: 09/01/15 - 08/31/16

DESCRIPTION (provided by applicant): Cancer is the second leading cause of death after heart disease in the US. Chemotherapy is a mainstay of treatment after surgical removal of tumors; but the balance of clinical benefit versus disabling or life- threatening side effects is often uncertain. Genotyping of cancers to identify mutated oncogenes ha...

Phase 2 STTR

Agency: Department of Health & Human Services
Topic: PA-13-235
Budget: 09/01/14 - 08/31/15

DESCRIPTION (provided by applicant): Cancer is the second leading cause of death after heart disease in the US. Chemotherapy is a mainstay of treatment after surgical removal of tumors;but the balance of clinical benefit versus disabling or life- threatening side effects is often uncertain. Genotyping of cancers to identify mutated oncogenes has...

Phase 1 STTR

Agency: Department of Health & Human Services
Topic: PA-12-100
Budget: 09/01/13 - 08/31/14

In the United States colorectal cancer (CRC) is the third leading cause of cancer mortality. Surgery is the primary treatment for early stage CRC;but adjuvant therapy is usually needed in advanced disease. Approximately 55% of CRC patients have metastatic disease for which the prognosis is poor despite incremental improvements due to introductio...

Phase 1 STTR

Agency: Department of Health & Human Services
Topic: PA-12-089
Budget: 07/02/13 - 06/30/14

DESCRIPTION (provided by applicant): In the United States, around 76,250 new cases of melanoma and 9,180 melanoma-related deaths are predicted for 2012. With the therapeutic options currently available, metastatic melanoma patients face the bleak prospect of at best, 10 month's survival and a one-in-ten chance of surviving for 10 years. Surgery ...

Phase 1 STTR

Agency: Department of Health & Human Services
Topic: PA-14-077
Budget: 07/02/13 - 06/30/15

DESCRIPTION (provided by applicant): In the United States, around 76,250 new cases of melanoma and 9,180 melanoma-related deaths are predicted for 2012. With the therapeutic options currently available, metastatic melanoma patients face the bleak prospect of at best, 10 month's survival and a one-in-ten chance of surviving for 10 years. Surgery ...

Phase 1 STTR

Agency: Department of Health & Human Services
Topic: PA-12-089
Budget: 09/24/12 - 08/31/13

DESCRIPTION (provided by applicant): In the United States colorectal cancer (CRC) is the third leading cause of cancer mortality. Surgery is the primary treatment for early stage CRC;but adjuvant therapy is usually needed in advanced disease. Approximately 55% of CRC patients have metastatic disease for which the prognosis is poor despite increm...

Phase 1 STTR

Agency: Department of Health & Human Services
Topic: PA-10-051
Budget: 09/23/11 - 08/31/13

DESCRIPTION (provided by applicant): Cancer is America's second leading cause of death. Many approved cancer drugs, such as bortezomib (Velcade), are cytotoxic agents that kill normal cells as well as tumor cells. Therapeutic benefit depends on tumor cells being more sensitive than normal cells, thereby allowing clinical responses to be achieved...